Giuseppe Fotia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giuseppe Fotia has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Vingiani
Oncology and Hematology-Oncology Department, School of Medicine, University of Milan, Milan, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
11 shared publications - Davide Massa
Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy
11 shared publications - Federica Miglietta
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy
11 shared publications - Federico Piacentini
Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy
11 shared publications - Maria Vittoria Dieci
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
11 shared publications - Valentina Guarneri
Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy
11 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Purpose:The purpose of this study was to assess prognosis of estrogen receptor (ER)–low expression and its dynamics in HER2− metastatic breast cancer and to compare sensitivity to nivolumab between ER-low and triple-negative breast cancer (TNBC).Experimental Design:Two cohorts were analyzed: a multicenter cohort of 982 patients with HER2− metastatic breast cancer and one prospective cohort of 110 patients with ER <10%/HER2− metastatic breast cancer enrolled in the TONIC trial (testing nivolumab). Endpoints were overall survival (OS) and post-relapse survival (PRS) in the retrospective cohort and progression-free survival, OS, and clinical benefit rate in the TONIC trial.Results:A total of 7.3% of retrospective cases had ER-low breast cancer, 15 of 110 of the TONIC trial. In the retrospective cohort, patients with ER-low breast cancer had significantly poorer OS (P < 0.001) and numerically shorter PRS (P = 0.230) compared with ER+/HER2− breast cancer and numerically longer OS (P = 0.098) and significantly longer PRS (P = 0.017) compared with TNBC. In the TONIC trial, patients with ER-low breast cancer, compared with TNBC, showed similar response to nivolumab (clinical benefit rate: 20.0% vs. 22.1%; P = 1), progression-free survival (median, 1.7 vs. 2.0 months; P = 0.5), and OS (median, 5.3 vs. 8.6 months; P = 0.3). Among patients with primary ER+/HER2− breast cancer (n = 565), the conversion toward ER-low breast cancer or TNBC at metastasis conferred independent negative prognostic impact both for OS (P = 0.002 and P = 0.001, respectively) and PRS (P = 0.018 and P = 0.001, respectively).Conclusions:We provided evidence of the prognostic role of ER-low expression and its dynamics in patients with HER2− metastatic breast cancer. We offered insights into sensitivity to anti-PD1 in metastatic breast cancer, showing that patients with ER-low breast cancer have comparable likelihood of responding to nivolumab as those with TNBC.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Purpose:The purpose of this study was to assess prognosis of estrogen receptor (ER)–low expression and its dynamics in HER2− metastatic breast cancer and to compare sensitivity to nivolumab between ER-low and triple-negative breast cancer (TNBC).Experimental Design:Two cohorts were analyzed: a multicenter cohort of 982 patients with HER2− metastatic breast cancer and one prospective cohort of 110 patients with ER <10%/HER2− metastatic breast cancer enrolled in the TONIC trial (testing nivolumab). Endpoints were overall survival (OS) and post-relapse survival (PRS) in the retrospective cohort and progression-free survival, OS, and clinical benefit rate in the TONIC trial.Results:A total of 7.3% of retrospective cases had ER-low breast cancer, 15 of 110 of the TONIC trial. In the retrospective cohort, patients with ER-low breast cancer had significantly poorer OS (P < 0.001) and numerically shorter PRS (P = 0.230) compared with ER+/HER2− breast cancer and numerically longer OS (P = 0.098) and significantly longer PRS (P = 0.017) compared with TNBC. In the TONIC trial, patients with ER-low breast cancer, compared with TNBC, showed similar response to nivolumab (clinical benefit rate: 20.0% vs. 22.1%; P = 1), progression-free survival (median, 1.7 vs. 2.0 months; P = 0.5), and OS (median, 5.3 vs. 8.6 months; P = 0.3). Among patients with primary ER+/HER2− breast cancer (n = 565), the conversion toward ER-low breast cancer or TNBC at metastasis conferred independent negative prognostic impact both for OS (P = 0.002 and P = 0.001, respectively) and PRS (P = 0.018 and P = 0.001, respectively).Conclusions:We provided evidence of the prognostic role of ER-low expression and its dynamics in patients with HER2− metastatic breast cancer. We offered insights into sensitivity to anti-PD1 in metastatic breast cancer, showing that patients with ER-low breast cancer have comparable likelihood of responding to nivolumab as those with TNBC.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Multivariate analysis for overall survival and post relapse survival in the retrospective cohort in patients with ER+/HER2- primary BC. Multivariable Cox proportional hazards analyses for overall survival and post-relapse survival in the retrospective cohort of patients with primary ER+/HER2- breast cancer; hazard ratios (HRs) with 95% confidence intervals and p-values are reported.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Multivariate analysis for overall survival and post relapse survival in the retrospective cohort in patients with ER+/HER2- primary BC. Multivariable Cox proportional hazards analyses for overall survival and post-relapse survival in the retrospective cohort of patients with primary ER+/HER2- breast cancer; hazard ratios (HRs) with 95% confidence intervals and p-values are reported.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Representativeness of Study Participants. Representativeness of study participants in the context of advanced breast cancer, with information on sex, age, race/ethnicity, geography, and overall comparability to the general patient population.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Representativeness of Study Participants. Representativeness of study participants in the context of advanced breast cancer, with information on sex, age, race/ethnicity, geography, and overall comparability to the general patient population.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Genes up-regulated or down-regulated in estrogen-receptor (ER)-low (ER 1-9%) vs ER-positive (>10%) by quantitative Significance Analysis of Microarrays (SAM) analysis List of genes significantly up- or down-regulated in tumors that switched from ER+/HER2– to ER-low (1–9%) compared with tumors maintaining a stable ER-positive (≥10%) phenotype, as identified by quantitative Significance Analysis of Microarrays (SAM).
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Genes up-regulated or down-regulated in estrogen-receptor (ER)-low (ER 1-9%) vs ER-positive (>10%) by quantitative Significance Analysis of Microarrays (SAM) analysis List of genes significantly up- or down-regulated in tumors that switched from ER+/HER2– to ER-low (1–9%) compared with tumors maintaining a stable ER-positive (≥10%) phenotype, as identified by quantitative Significance Analysis of Microarrays (SAM).
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Evolution of PD-L1 status from primary BC to relapse according to phenotypic evolution from primary BC to metastases. Sankey plots showing the evolution of PD-L1 status from primary breast cancer to relapse, according to phenotypic evolution (stable triple-negative breast cancer, from ER+/HER2- to ER-low, and from ER+/HER2- to triple-negative breast cancer).
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Evolution of PD-L1 status from primary BC to relapse according to phenotypic evolution from primary BC to metastases. Sankey plots showing the evolution of PD-L1 status from primary breast cancer to relapse, according to phenotypic evolution (stable triple-negative breast cancer, from ER+/HER2- to ER-low, and from ER+/HER2- to triple-negative breast cancer).
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Most relevant findings from the signature comparisons (analysis of 770 genes) in ER-low and TNBC metastatic samples from the TONIC trial. Boxplots showing differential expression of ESR1 and selected immune-related signatures in ER-low and triple-negative metastatic samples from the TONIC trial.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Most relevant findings from the signature comparisons (analysis of 770 genes) in ER-low and TNBC metastatic samples from the TONIC trial. Boxplots showing differential expression of ESR1 and selected immune-related signatures in ER-low and triple-negative metastatic samples from the TONIC trial.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Distribution of PAM50 intrinsic subtypes across ER-low, TN and ER-low metastatic samples of patients with ER+/HER2- primary tumors. Donut plots showing the distribution of PAM50 intrinsic subtypes in metastatic samples from patients with ER+/HER2- primary breast cancer, according to phenotypic evolution (conversion to ER-low, conversion to triple-negative, or stable ER+/HER2-).
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Distribution of PAM50 intrinsic subtypes across ER-low, TN and ER-low metastatic samples of patients with ER+/HER2- primary tumors. Donut plots showing the distribution of PAM50 intrinsic subtypes in metastatic samples from patients with ER+/HER2- primary breast cancer, according to phenotypic evolution (conversion to ER-low, conversion to triple-negative, or stable ER+/HER2-).
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Clinicopathological features according to ER expression in the TONIC trial cohort Clinicopathological features of patients in the TONIC trial cohort, reported according to ER expression status (ER-low vs ER-0).
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Clinicopathological features according to ER expression in the TONIC trial cohort Clinicopathological features of patients in the TONIC trial cohort, reported according to ER expression status (ER-low vs ER-0).
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Workflow of the study. The flow diagram of the study shows an overview of the two cohorts and the analyses performed.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
Workflow of the study. The flow diagram of the study shows an overview of the two cohorts and the analyses performed.